On November 9, 2021 Vyant Bio, Inc. ("Vyant Bio", "Company") (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases (Press release, Vyant Bio, NOV 9, 2021, View Source [SID1234595122]). Today, Vyant Bio reported that an investor conference call and webcast will be hosted on Thursday, November 11, 2021 .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jay Roberts, Chief Executive Officer, and Andy LaFrence, Chief Financial Officer, of Vyant Bio will highlight corporate, scientific, financial, and operational results achieved in the third quarter of 2021. Please also visit the Investors section of the Vyant Bio web site for details on how to participate.

The live event will be recorded and available for replay. The conference call and webcast details are also included inside the Investors section of the Vyant Bio corporate website at www.vyantbio.com.